It could become an investor class action.
Wounded blood testing startup Theranos just got hit with another major legal buzz saw—one that could snowball into a class action tussle with its investors.
The latest suit, filed Monday by Robert Colman, co-founder of investment firm Robertson Stephens, and another private defendant and Theranos share purchaser named Hilary Taubman-Dye, alleges that Theranos consistently and deliberately misled its investors through outsize claims about its technology's capabilities and potential to transform diagnostic testing.
